Encouraging Phase III Results for ARCA Biopharma, Inc. (NASDAQ:ABIO)

LOS ANGELES - 05/12/09 - BioMedReports, the news portal covering the biomedical news and financial sector is tracking ARCA biopharma, Inc. (ARCA), formerly Nuvelo, Inc. as their lead product candidate Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator is under review by the United States Food and Drug Administration (FDA), for chronic heart failure (HF).

Arca biopharma has reported data from the pivotal Phase III Best trial of Gencaro in patients with advanced chronic heart failure. The trial results demonstrated that, in a demographically diverse group of primarily US patients with New York Heart Association class III and IV heart failure, Gencaro treatment resulted in a near significant overall survival benefit and statistically significant benefits in slowing progression of heart failure.

Gencaro (bucindolol) NDA for the treatment of chronic heart failure has a PDUFA decision date of 5/31/09.

A full report on the developments appears today at BioMedReports.Com.

####

About BioMedReports.Com

BioMedReports.com is a news portal covering the biomedical news and financial sector. It features its own blog, discussion forum, stock research reports, news feeds, videos, press release capability, stock commentaries, and other unique content - including FDA and Clinical Trial Calendars plus a database that includes about 1,000 stocks and exchange-traded funds from the healthcare sector which are organized into various new healthcare stock indexes.

For more biomedical sector and investment news, go to www.BioMedReports.com

Disclosure: No positions.

Certain sections of this report contain forward-looking statements that are based on our reporters’ expectations, estimates, projections and assumptions. Words such as “expects,” “anticipates,” “plans,” “believes,” “scheduled,” “estimates” and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.

All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company’s behalf are qualified by the cautionary statements in this section. BiomedReports.Com does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.

Contact Information

M.E. Garza

Editor

BioMedReports.Com

Contact via E-mail